
Ioline D Henter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3534630/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Authors' Reply to Pappagallo et al.: Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status― CNS Drugs, 2022, 36, 205-206.	5.9	3
2	Ketamine treatment for depression: a review. Discover Mental Health, 2022, 2, 9.	2.0	37
3	Cyclooxygenases as Potential PET Imaging Biomarkers to Explore Neuroinflammation in Dementia. Journal of Nuclear Medicine, 2022, 63, 53S-59S.	5.0	6
4	The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response. Molecular Psychiatry, 2021, 26, 4085-4095.	7.9	48
5	Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants. International Journal of Neuropsychopharmacology, 2021, 24, 8-21.	2.1	58
6	Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status. CNS Drugs, 2021, 35, 527-543.	5.9	74
7	A wake-up call: Sleep physiology and related translational discrepancies in studies of rapid-acting antidepressants. Progress in Neurobiology, 2021, 206, 102140.	5.7	6
8	Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. Lancet Psychiatry,the, 2020, 7, 1064-1074.	7.4	149
9	PET measurement of cyclooxygenase-2 using a novel radioligand: upregulation in primate neuroinflammation and first-in-human study. Journal of Neuroinflammation, 2020, 17, 140.	7.2	35
10	Neurobiological biomarkers of response to ketamine. Advances in Pharmacology, 2020, 89, 195-235.	2.0	21
11	A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression. International Journal of Neuropsychopharmacology, 2020, 23, 417-425.	2.1	42
12	Not So Fast. Journal of Clinical Psychiatry, 2020, 81, .	2.2	6
13	The influence of ketamine on drug discovery in depression. Drug Discovery Today, 2019, 24, 2033-2043.	6.4	57
14	Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments. International Journal of Neuropsychopharmacology, 2019, 22, 119-135.	2.1	116
15	Glutamatergic Modulators in Depression. Harvard Review of Psychiatry, 2018, 26, 307-319.	2.1	70
16	PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects. EJNMMI Research, 2018, 8, 57.	2.5	144
17	Are 24-hour motor activity patterns associated with continued rapid response to ketamine?. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2739-2748.	2.2	14
18	Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Translational Psychiatry, 2018, 8, 280.	4.8	26

IOLINE D HENTER

#	Article	IF	CITATIONS
19	Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia. Advances in Pharmacology, 2018, 82, 163-185.	2.0	32
20	New targets for rapid antidepressant action. Progress in Neurobiology, 2017, 152, 21-37.	5.7	118
21	Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders. Neuropsychopharmacology, 2017, 42, 787-800.	5.4	37
22	Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects. Journal of Psychiatric Research, 2017, 86, 55-57.	3.1	2
23	Potential Novel Treatments in Bipolar Depression. Milestones in Drug Therapy, 2016, , 259-285.	0.1	Ο
24	Glutamate Receptor Antagonists as Fast-Acting Therapeutic Alternatives for the Treatment of Depression: Ketamine and Other Compounds. Annual Review of Pharmacology and Toxicology, 2014, 54, 119-139.	9.4	140
25	Antidepressant effects on serotonin 1A/1B receptors in the rat brain using a gene x environment model. Neuroscience Letters, 2014, 559, 163-168.	2.1	16
26	Defining anxious depression: a review of the literature. CNS Spectrums, 2013, 18, 252-260.	1.2	83
27	Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study. Neuropsychopharmacology, 2012, 37, 1526-1533.	5.4	262
28	Targeting the Glutamatergic System to Treat Major Depressive Disorder. Drugs, 2012, 72, 1313-1333.	10.9	181
29	Serotonin-1A receptors in major depression quantified using PET: Controversies, confounds, and recommendations. Neurolmage, 2012, 59, 3243-3251.	4.2	69
30	Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacology Biochemistry and Behavior, 2012, 100, 678-687.	2.9	77
31	The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments. Pharmaceuticals, 2010, 3, 19-41.	3.8	168
32	Glutamatergic Modulators: The Future of Treating Mood Disorders?. Harvard Review of Psychiatry, 2010, 18, 293-303.	2.1	203
33	Partial Rodent Genetic Models for Bipolar Disorder. Current Topics in Behavioral Neurosciences, 2010, 5, 89-106.	1.7	6
34	Bipolar Disorder: A Neurobiological Synthesis. Current Topics in Behavioral Neurosciences, 2010, 5, 331-340.	1.7	7
35	Presynaptic Glutamatergic Dysfunction in Bipolar Disorder. Biological Psychiatry, 2010, 67, 1007-1009.	1.3	40
36	Rapid Resolution of Suicidal Ideation After a Single Infusion of an <i>N</i> -Methyl- <scp>D</scp> -Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder. Journal of Clinical Psychiatry, 2010, 71, 1605-1611.	2.2	487

IOLINE D HENTER

#	Article	IF	CITATIONS
37	Dr Salvadore and Colleagues Reply. Journal of Clinical Psychiatry, 2010, 71, 1698-1700.	2.2	0
38	A role for PKC in mediating stress-induced prefrontal cortical structural plasticity and cognitive function. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17613-17614.	7.1	11
39	Animal models of suicide-trait-related behaviors. Trends in Pharmacological Sciences, 2009, 30, 165-173.	8.7	56
40	The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues in Clinical Neuroscience, 2009, 11, 333-348.	3.7	100
41	Early intervention in bipolar disorder, part II: therapeutics. Microbial Biotechnology, 2008, 2, 136-146.	1.7	22
42	Early intervention in bipolar disorder, part I: clinical and imaging findings. Microbial Biotechnology, 2008, 2, 122-135.	1.7	24
43	Adverse events during a placebo phase for inpatients with chronic schizophrenia. Biological Psychiatry, 2001, 50, 487-492.	1.3	3
44	Lithium revisited: savings brought about by the use of lithium, 1970-1991. Psychiatric Quarterly, 2001, 72, 149-166.	2.1	7
45	The long-term effects of placebo in patients with chronic schizophrenia. Biological Psychiatry, 1999, 46, 1092-1105.	1.3	28
46	The effects of early and sustained intervention on the long-term morbidity of schizophrenia. Journal of Psychiatric Research, 1998, 32, 169-177.	3.1	69